The Leukemia & Lymphoma Society applauds the U.S. Food and Drug Administration's approval today of a new drug for patients with multiple myeloma.
POMALYST® (pomalidomide) is indicated for patients with multiple myeloma who have received at least two prior therapies including lenalidomide and bortezomib and have demonstrated disease progression on or within 60 days of completion of the last therapy.
"This approval gives hope to patients with multiple myeloma who have relapsed or are refractory to other therapies," said Hildy Dillon, The Leukemia & Lymphoma Society's senior vice president of patient services. "LLS has supported much research to advance this class of drugs – immunomodulatory agents. Although there have been many therapies approved for myeloma in the past decade, patients with this disease tend to relapse, or are resistant to those therapies. This medication is an important new option for patients with urgent needs."